Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice.

Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement. Drugs Context (2016) 0.75

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23

A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost (1993) 7.92

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost (2005) 5.92

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation (2014) 4.56

Natural language processing: an introduction. J Am Med Inform Assoc (2011) 3.50

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation (2008) 2.98

A study of machine-learning-based approaches to extract clinical entities and their assertions from discharge summaries. J Am Med Inform Assoc (2011) 2.70

Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes (2008) 2.61

Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol (2013) 2.29

National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes (2012) 2.27

Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med (2007) 2.20

A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf (2012) 2.11

Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm (2009) 2.08

Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 1.81

Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost (2010) 1.68

Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med (2012) 1.65

Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes (2010) 1.50

Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res (2008) 1.47

Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes (2010) 1.39

30-day mortality and readmission after hemorrhagic stroke among Medicare beneficiaries in Joint Commission primary stroke center-certified and noncertified hospitals. Stroke (2011) 1.29

Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol (2013) 1.20

National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation (2014) 1.19

30-Day risk-standardized mortality and readmission rates after ischemic stroke in critical access hospitals. Stroke (2012) 1.02

National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. Ann Pharmacother (2013) 0.92

Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients. Thromb Haemost (2011) 0.90

Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc (2014) 0.85

Quality of warfarin control affects the incidence of stroke in elderly patients with atrial fibrillation. Intern Med (2010) 0.83

Apixaban compared with warfarin for stroke prevention in atrial fibrillation: implications of time in therapeutic range. Circulation (2013) 0.82

Natural language processing and electronic medical records. JAMA (2011) 0.79

Evaluation of practice patterns in the treatment of atrial fibrillation among the commercially insured. Curr Med Res Opin (2014) 0.77